2. Academic Validation
  3. Network pharmacology predicted HDAC6 as a potential target of flavones from Daphne giraldii on hepatocellular carcinoma

Network pharmacology predicted HDAC6 as a potential target of flavones from Daphne giraldii on hepatocellular carcinoma

  • Nat Prod Res. 2021 Sep;35(18):3171-3175. doi: 10.1080/14786419.2019.1693563.
Jing-Jie Chen 1,  Xin-Yue Shang 1,  Feng-Ying Han 1,  Yue Zhang 1,  Dian Zhao 1,  Guo-Dong Yao 1,  Shao-Jiang Song 1
Affiliations

Affiliation

  • 1 Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
PMID: 31741408 DOI: 10.1080/14786419.2019.1693563
Abstract

Daphne giraldii Nitsche, belongs to Daphne genus, has been reported to exert anti-tumor activities. Our previous study suggested that Flavones from Daphne giraldii have significant inhibitory effects on hepatocellular carcinoma (HCC) cells. However, the potential target of this type flavone was still unknown. In this study, 74 Flavonoids compounds of Daphne giraldii and 41 potential targets of HCC were analyzed by the network, the most potential target was histone deacetylase 6 (HDAC6). Considering the cytotoxicity, compound 70 (Daphnegiravone D, DGD) was chosen for further confirmation. Molecular docking study revealed that DGD formed high binding affinity with HDAC6. Concomitantly, pharmacological studies indicated that DGD could inhibit the expression of HDAC6 in vitro and in vivo. In this study, network pharmacology along with experimental validation predicted and verified HDAC6 as one of potential targets of Flavones, these investigations provide a new insight for further study of Daphne giraldii on HCC treatment.

Keywords

Daphne giraldii; flavone; hepatocellular carcinoma; histone deacetylase 6; network pharmacology.

Figures
Products